Intravitreal Bevacizumab for Refractory Pseudophakic Cystoid Macular Edema The Pan-American Collaborative Retina Study Group Results
Objective: To determine the feasibility, safety, and clinical effect of intravitreal (IVT) bevacizumab (Avastin; Genentech, Inc., San Francisco, CA) in patients with refractory cystoid macular edema (CME) after cataract surgery. Design: Interventional, retrospective, multicenter study.
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 2009
- Institución:
- Universidad del Rosario
- Repositorio:
- Repositorio EdocUR - U. Rosario
- Idioma:
- eng
- OAI Identifier:
- oai:repository.urosario.edu.co:10336/26147
- Acceso en línea:
- https://doi.org/10.1016/j.ophtha.2009.04.006
https://repository.urosario.edu.co/handle/10336/26147
- Palabra clave:
- Aged
Aged
80 and over
Angiogenesis Inhibitors
Antibodies
Monoclonal
Antibodies
Monoclonal
Humanized
Bevacizumab
Cataract Extraction
Feasibility Studies
Female
Fluorescein Angiography
Follow-Up Studies
Humans
Injections
Macular Edema
Male
Postoperative Complications
Pseudophakia
Retrospective Studies
Tomography
Optical Coherence
Treatment Outcome
Vascular Endothelial Growth Factor A
Visual Acuity
Vitreous Body
- Rights
- License
- Restringido (Acceso a grupos específicos)